Holen Sie sich die Stockscreener-App
10.57
1.03%
-0.11
Handel nachbörslich:
10.14
-0.43
-4.07%
Schlusskurs vom Vortag:
$10.68
Offen:
$10.8
24-Stunden-Volumen:
1.57M
Relative Volume:
1.83
Marktkapitalisierung:
$725.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-96.66M
KGV:
-4.9163
EPS:
-2.15
Netto-Cashflow:
$-83.73M
1W Leistung:
-4.77%
1M Leistung:
+35.34%
6M Leistung:
+209.97%
1J Leistung:
-5.29%
1-Tages-Spanne:
$10.39
$11.34
1-Wochen-Bereich:
$10.23
$11.46
52-Wochen-Spanne:
$2.86
$13.51
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Firmenname
Olema Pharmaceuticals Inc
Sektor
Branche
Telefon
(415) 651-3316
Adresse
780 BRANNAN STREET, SAN FRANCISCO
Vergleichen Sie OLMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
10.57 | 733.01M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-12 | Bestätigt | Citigroup | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2024-01-30 | Eingeleitet | Citigroup | Buy |
| 2023-07-21 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-05 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-22 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-12-14 | Eingeleitet | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
Visual trend scoring systems applied to Olema Pharmaceuticals Inc.2025 Major Catalysts & Fast Exit and Entry Strategy Plans - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Olema Pharmaceuticals (NASDAQ:OLMA) - MarketBeat
Can momentum traders help lift Olema Pharmaceuticals Inc.2025 Performance Recap & Fast Momentum Entry Tips - newser.com
Guggenheim Begins Coverage on Olema Pharmaceuticals (NASDAQ:OLMA) - Defense World
Does Olema Pharmaceuticals Inc. fit your quant trading modelEarnings Risk Summary & Risk Controlled Swing Trade Alerts - newser.com
Is now a turning point for Olema Pharmaceuticals Inc.2025 Growth vs Value & Consistent Income Trade Recommendations - newser.com
Why Olema Pharmaceuticals Inc. stock attracts global investorsTrade Entry Report & Low Drawdown Momentum Trade Ideas - newser.com
Will Olema Pharmaceuticals Inc. benefit from macro trendsMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com
Farther Finance Advisors LLC Grows Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA - Defense World
Guggenheim Initiates Coverage on OLMA with a 'Buy' Rating and $2 - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Target Price at $24.00 - Defense World
What analysts say about Olema Pharmaceuticals Inc stockAnalyst Upgrades & Low Cost Portfolio Ideas - earlytimes.in
How moving averages guide Olema Pharmaceuticals Inc. tradingStop Loss & Stock Portfolio Risk Control - newser.com
How analysts rate Olema Pharmaceuticals Inc. stock todayEarnings Growth Report & Expert Verified Movement Alerts - newser.com
Will Olema Pharmaceuticals Inc. stock deliver better than expected guidanceQuarterly Profit Review & Step-by-Step Swing Trade Plans - newser.com
How to forecast Olema Pharmaceuticals Inc. trends using time seriesJuly 2025 Spike Watch & Weekly Chart Analysis and Trade Guides - newser.com
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Metastatic HR+/HER2− Breast Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Arvinas, Olema Pharma, Sichuan Baili Pharma, Ana C Garrido-Castro - Barchart.com
Metastatic HR+/HER2 Breast Cancer Market Positioned - openPR.com
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Chart based exit strategy for Olema Pharmaceuticals Inc.Watch List & Stepwise Entry and Exit Trade Signals - newser.com
Cancer stocks rebound, outpacing broader markets in Q3 2025 - BioWorld MedTech
77,000-share award: Olema Pharmaceuticals grants stock options at $11.04 as inducement - Stock Titan
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 6.3%Time to Sell? - MarketBeat
Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA) - Insider Monkey
11 Best Fast Money Stocks to Buy Now - Insider Monkey
What drives Olema Pharmaceuticals Inc stock priceVolume Spike Alerts & Accelerated Financial Growth - earlytimes.in
Finanzdaten der Olema Pharmaceuticals Inc-Aktie (OLMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Olema Pharmaceuticals Inc-Aktie (OLMA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Harmon Cyrus | Director |
Sep 16 '25 |
Sale |
8.04 |
10,000 |
80,400 |
754,140 |
| Harmon Cyrus | Director |
Sep 18 '25 |
Sale |
8.32 |
3,086 |
25,676 |
117,028 |
| Harmon Cyrus | Director |
Sep 16 '25 |
Sale |
8.08 |
1,914 |
15,465 |
120,114 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):